Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNK01001 in Ankylosing Spondylitis
NCT06085534Phase 2Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zemprocitinib in ankylosing spondylitis (AS) (3 arms), sponsored by Lynk Pharmaceuticals. Primary endpoint: Assessment of SpondyloArthritis international Society 40% improvement at 12 weeks. Started Jan 2022; status: completed.
02
Drugs
zemprocitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT06085534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085534.